Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin - AM2019
This panel focused on the guideline recommendations and videntiary base for radiation treatment of basal and squamous cell cancers of the skin. The multidisciplinary panel includes representation from the American Academy of Dermatology, American Society of Clinical Oncology, American Society of Dermatopathology, and the Society of Surgical Oncology. The guideline includes recommendations for cutaneous BCC and SCC skin cancer on definitive and post-operative radiation therapy. It discusses preferred techniques and dose-fractionation schedules as well as the appropriate use of systemic agents, including immunotherapy, with radiation in the neoadjuvant, adjuvant, and concurrent settings. Finally, the ASTRO guideline development process and the systematic review parameters for this guideline will be briefly presented.
The meeting is designed to meet the interests of radiation oncologists, medical oncologists, surgeons, radiation physicists, specialists, and residents.
- Demonstrate familiarity with the process of guideline development, systematic review methodology, and assessment of strength of recommendations and quality of evidence.
- Identify and describe the major clinical trials relevant to basal and squamous cell skin cancer.
- Apply evidence-based ASTRO guideline recommendations to clinical practice.
The following persons served as faculty for this activity:
Christopher Barker, MD is employed at Memorial Sloan Kettering Cancer Center and has nothing to disclose.
Lisa Bradfield, CAE is employed at ASTRO and has nothing to disclose.
Phillip Devlin, MD, FACR, FASTRO, FFRRCSI, FASTRO is employed at Brigham and Women’s Hospital and Dana-Farber Cancer Institute and has nothing to disclose.
Jessica Geiger, MD receives compensation/remuneration/funding from Regeneron and Roche/Genentech.
Anna Likhacheva, MD, MPH is employed at Sutter Health and has nothing to disclose.
Sandra Zaky, MD, MS, BS is employed at Stanford Radiation Oncology and has nothing to disclose.
Additionally, the Education and CME/MOC Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
- 1.25 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.
- No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
- No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
- ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.